Creative Biolabs' service focuses on LPP—second-gen non-viral vectors (ternary complexes: polycation-condensed nucleic acid core and lipid bilayer shell) for mRNA/DNA delivery, synergizing polyplex protection and liposome stability to overcome delivery barriers.
It uses advanced multicompartmental LPP technology to ensure superior stability, targeted high-efficiency delivery, precise co-delivery of multiple molecules, and achieves specific synergistic immune programming for next-gen genetic medicines.
Discover How We Can Help - Request a Consultation
The LPP system is a powerful, versatile nanocarrier platform designed to enhance the safety and efficacy of genetic medicines.
Fig.1 Schematic diagram of the in vivo immune mechanism of LPP-mRNA vaccine.1
The superior customization and control afforded by LPPs make them ideal for complex applications:
To initiate the service, clients provide:
Review client’s payload, target tissue, functional goals; select optimal polymer (e.g., PbAE) and lipid components (e.g., EDOPC/DOPE/DSPE-PEG).
Cationic polymer complexes with nucleic acid(s) to form a condensed polyplex core; the core is encapsulated in a custom lipid shell.
Test via DLS (size/PDI), Zeta potential measurement, TEM (morphology, ~50 nm core detection).
Test LPP on client-specified APCs/cell lines; measure transfection efficiency and viability; compare with benchmark systems.
Scale up optimized LPP; conduct comprehensive QC (mRNA integrity, endotoxin testing).
As an expert in biology, you know that the true challenge in genetic medicine is not sequencing the payload, but successfully delivering it. Creative Biolabs' Custom Lipopolyplex Development Service is your strategic delivery solution, engineered to eliminate the bottlenecks of stability, cell uptake, and endosomal escape.
Offer one-stop development with custom selection and tuning of the core-shell structure—including polymer (e.g., PbAE), N:P ratio, lipid composition (e.g., EDOPC/DOPE), and surface PEGylation—to meet requirements of your specific in vivo model or IND pathway.
Use a unique multicompartmental platform to ensure precise, simultaneous co-delivery of dual payloads (e.g., mRNA and plasmid DNA) into the same target cell, providing localized, synergistic signals for effective T cell priming in vaccine development.
The hybrid core-shell system enhances protection of fragile mRNA and DNA from serum nucleases, extending circulation half-life and ensuring higher-fidelity delivery to intended target cells.
Engineer the LPP surface for high-efficiency uptake by professional Antigen-Presenting Cells (APCs) via macropinocytosis; achieve superior endosomal escape through the polymer core's proton sponge effect.
Each custom LPP batch comes with stringent physicochemical and biological QC reports, validating size, PDI, encapsulation efficiency, and in vitro viability data to enable seamless R&D-to-preclinical transition.
Experience the Creative Biolabs Advantage - Get a Quote Today
LPP is a hybrid vector, combining a condensed polyplex core with a lipid shell, while LNPs are typically micelles or vesicles that encapsulate mRNA. LPP's structured core offers superior condensation and protection, and its multicompartmental nature is uniquely suited for stoichiometric co-delivery of two distinct therapeutic payloads (mRNA and plasmid)—a feature often challenging to achieve with high efficiency in simple LNPs.
Yes, absolute customization is a core feature of our service. We can modify the lipid shell composition (including incorporating surface-modifying lipids or targeting moieties, if available) to influence biodistribution and enhance uptake by specific cell populations, such as Dendritic Cells in the spleen or lymph nodes. Our team is ready to discuss your specific targeting requirements.
Stoichiometric control means the precise, pre-defined ratio of your antigen (mRNA) to your immune adjuvant (e.g., cytokine plasmid) is guaranteed in every LPP particle delivered to the APC. This ensures the cell receives the exact simultaneous signals needed for optimal T cell priming, preventing insufficient or excessive immune activation often seen when these components are delivered separately or non-specifically.
Our rigorous QC process includes verifying the absence of unencapsulated mRNA, confirming no aggregation via PDI analysis, measuring low endotoxin levels, and performing low-cytotoxicity testing on target cell lines. Final formulations are optimized to be stable and safe for preclinical applications.
The service delivers top-tier engineering control and validated performance in non-viral delivery. It provides superior stability, APC targeting, and unique stoichiometric co-delivery capability, empowering researchers to develop next-generation genetic medicines with enhanced potency and safety.
Contact Our Team for More Information and to Discuss Your Project
| Cat. No | Product Name | Promoter |
|---|---|---|
| CAT#: GTVCR-WQ001MR | IVTScrip™ pT7-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ002MR | IVTScrip™ pT7-VEE-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ003MR | IVTScrip™ pT7-VEE-mRNA-FLuc Vector | T7 |
| CAT#: GTVCR-WQ87MR | IVTScrip™ pT7-VEE-mRNA-Anti-SELP, 42-89-glycoprotein Vector | T7 |
| Cat. No | Product Name | Type |
|---|---|---|
| CAT#: GTTS-WQ001MR) | IVTScrip™ mRNA-EGFP (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| CAT#: GTTS-WK18036MR | IVTScrip™ mRNA-Human AIMP2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) | Enzyme mRNA |
| (CAT#: GTTS-WQ004MR) | IVTScrip™ mRNA-Fluc (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| (CAT#: GTTS-WQ009MR) | IVTScrip™ mRNA-β gal (Cap 1, 30 nt-poly(A)) | Reporter Gene |
Reference
